Artikel ; Online: Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria.
The New England journal of medicine
2024 Band 390, Heft 17, Seite(n) 1549–1559
Abstract: Background: Subcutaneous administration of the monoclonal antibody L9LS protected adults against controlled : Methods: We conducted a phase 2 trial in Mali to assess the safety and efficacy of subcutaneous administration of L9LS in children 6 to 10 ... ...
| Abstract | Background: Subcutaneous administration of the monoclonal antibody L9LS protected adults against controlled Methods: We conducted a phase 2 trial in Mali to assess the safety and efficacy of subcutaneous administration of L9LS in children 6 to 10 years of age over a 6-month malaria season. In part A of the trial, safety was assessed at three dose levels in adults, followed by assessment at two dose levels in children. In part B of the trial, children were randomly assigned, in a 1:1:1 ratio, to receive 150 mg of L9LS, 300 mg of L9LS, or placebo. The primary efficacy end point, assessed in a time-to-event analysis, was the first Results: No safety concerns were identified in the dose-escalation part of the trial (part A). In part B, 225 children underwent randomization, with 75 children assigned to each group. No safety concerns were identified in part B. Conclusions: Subcutaneous administration of L9LS to children was protective against |
|||||
|---|---|---|---|---|---|---|
| Mesh-Begriff(e) | Adult ; Child ; Female ; Humans ; Male ; Dose-Response Relationship, Drug ; Double-Blind Method ; Endemic Diseases/prevention & control ; Injections, Subcutaneous ; Kaplan-Meier Estimate ; Malaria, Falciparum/drug therapy ; Malaria, Falciparum/epidemiology ; Malaria, Falciparum/prevention & control ; Mali/epidemiology ; Plasmodium falciparum ; Treatment Outcome ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Directly Observed Therapy ; Artemether, Lumefantrine Drug Combination/administration & dosage ; Artemether, Lumefantrine Drug Combination/therapeutic use ; Young Adult ; Middle Aged | |||||
| Chemische Substanzen | Antibodies, Monoclonal, Humanized ; Artemether, Lumefantrine Drug Combination | |||||
| Sprache | Englisch | |||||
| Erscheinungsdatum | 2024-04-26 | |||||
| Erscheinungsland | United States | |||||
| Dokumenttyp | Journal Article ; Randomized Controlled Trial ; Clinical Trial, Phase II ; Research Support, Non-U.S. Gov't ; Multicenter Study ; Research Support, N.I.H., Extramural | |||||
| ZDB-ID | 207154-x | |||||
| ISSN | 1533-4406 ; 0028-4793 | |||||
| ISSN (online) | 1533-4406 | |||||
| ISSN | 0028-4793 | |||||
| DOI | 10.1056/NEJMoa2312775 | |||||
| Signatur |
|
|||||
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
| Ua VI Zs.34: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.